Extracts of the testes of man and animal have been used for some time to enhance performance of a variety of sorts. Medical use of steroids dates back several decades, and recent intense athletic and fitness (bodybuilding) competition has driven some to use and abuse of testosterone and synthetic derivatives in the quest for that extra edge, despite a knowledge that anabolic steroids carry significant risk for liver, endocrine, and psychiatric toxicity, and also carry criminal penalties and disciplinary risks for athletes and health care workers who promote and traffic these substances outside their established medical uses.
References
1.
WilsonJDGriffinJE:The Use and Misuse of Androgens. Metabolism291:1278–1295,1980.
2.
KoperaH:The History of Anabolic Steroids and a Review of Clinical Experience with Anabolic Steroids. Acta Endocrinologica2711:11–18,1985.
3.
HobermanJMYesalisCE: The History of Synthetic Testosterone. Scientific American, February 1995: 76–81.
4.
Position Stand: Blood Doping as an Ergogenic Aid. American College of Sports Medicine, MSSE19(5):540–543, 1987.
5.
USOC Guide to Prohibited Substances and Methods. U.S. Olympic Committee, March 1996.
6.
Position Stand: The Use of Anabolic-Androgenic Steroids in Sports. American College of Sports Medicine MSSE19(5):534–539, 1987.
7.
HauptHARovereGD:Anabolic Steroids: A Review of the Literature. The American Journal of Sports Medicine121:469–484,1984.
8.
StraussRH: Drugs and Performance in Sports, pp. 199–205, 1987.
9.
BhasinSStorerTWBermanN: The Effects of Supraphysiological Doses of Testosterone on Muscle Size and Strength in Normal Men. The New England Journal of Medicine, 335(1):1–7, July 4, 1996.
10.
MartinLG:Effect of Androgen on Growth Hormone Secretion and Growth in Boys with Short Stature. Acta Endocrinologica911:201–212,1979.
11.
DequekerJGeusensP:Anabolic Steroids and Osteoporosis. Acta Endocrinologica2711:45–52,1985.
12.
WilsonJDGriffinJE:The Use and Misuse of Androgens. Metabolism291:1278–1295,1980.
13.
KannelWB:New Perspectives on Cardiovascular Risk Factors. American Heart Journal1141:213–219,1987.
14.
McKenneyJM:Cholesterol and Coronary Heart Disease: The Link. Journal of Pharmacy Practice11:111–117,1988.
15.
GordenDJRifkindBM:High-Density Lipoprotein—The Clinical Implications of Recent Studies. New England Journal of Medicine3211:1311–1316,1989.
16.
ReevesRDMorrisMDBarbourGL:Hyperlipidemia Due to Oxymetholone Therapy. Journal of the American Medical Association2361:469–472,1976.
17.
McNuttRAFerenchickGSKirlinPCHamlinNJ:Acute Myocardial Infarction in a 22-Year-Old World Class Weight Lifter Using Anabolic Steroids. The American Journal of Cardiology621:164,1988.
18.
MochizukiRMRichterKJ:Cardiomyopathy and Cerebrovascular Accident Associated With Anabolic-Androgenic Steroid Use, The Physician and Sportsmedicine, e(11):109–114,1988.
19.
MaronBJRobertsWCMcAllisterHARosingDREpsteinSE:Sudden Death in Young Athletes. Circulation621:218–229,1980.
20.
BuckleyWE:Estimated Prevalence of Anabolic Steroid Use Among Male High School Seniors. Journal of the American Medical Association2601:3441–3445,1988.
21.
HallaganJBHallaganLFSnyderMB:Anabolic-Androgenic Steroid Use by Athletes. New England Journal of Medicine3211:1042–1045,1989.
22.
NagelbergSBLaueLLoriauxDLLiuLSherinsRJ:Cerebrovascular Accident Associated with Testosterone Therapy in a 21-Year-Old Hypogonadal Man. New England Journal of Medicine3141:649–650,1986.
23.
FrankelMAEichbergRZachariahSB:Anabolic Androgenic Steroids and a Stroke in an Athlete. Archives of Physical Medicine and Rehabilitation691:632–633,1988.
24.
LoweGDOThomsonJEReaveyMMForbesCDPrenticeCRM:Mesterolone: Thrombosis During Treatment, and a Study of Its Prothromobotic Effects. British Journal of Clinical Pharmacology71:107–109,1979.
25.
FerenchickGS:Are Androgenic Steroids Thrombogenic?New England Journal of Medicine3221:476,1990.
26.
NakaoJChangWCMuratoSIOrimoH:Testosterone Inhibits Prostacyclin Production by Rat Aortic Smooth Muscle Cells in Culture. Atherosclerosis391:203–209,1981.
27.
StraussRHLiggettMTLaneseRR:Anabolic Steroid Use and Perceived Effects in Ten Weight-Trained Women Athletes. Journal of the American Medical Association2531:2871–2873,1985.
28.
JacksonJAWaxmanJSpiekermanM:Prostatic Complications of Testosterone Replacement Therapy. Annals of Internal Medicine1491:2365–2366,1989.
29.
EhrenkranzJBlissESheardMH:Plasma Testosterone: Correlation with Aggressive Behavior and Social Dominance in Man. Psychosomatic Medicine361:469–475,1974.
30.
PopeHGKatzDL:Affective and Psychotic Symptoms Associated with Anabolic Steroid Use. American Journal of Psychiatry1451:487–490,1988.
31.
Haloperidol—Haldol, McNeill Laboratories, an anti-psychotic.
32.
Mesoridazine—Serentil, Boehringer, an antipsychotic.
33.
SklarekHM:AIDS in a Bodybuilder Using Anabolic Steroids. New England Journal of Medicine3111:1701,1984.
34.
KashkinKBKleberHD:Hooked on Hormones? An Anabolic Steroid Addiction Hypothesis. Journal of the American Medical Association2621:3166–3170,1989.
35.
BrowerKJBlowFCBeresfordTPFuellingC:Anabolic-Androgenic Steroid Dependence. Journal of Clinical Psychiatry501:31–33,1989.
36.
TennantFBlackDLVoyRO:Anabolic Steroid Dependence with Opioid-Type Features. New England Journal of Medicine3191:578,1988.
37.
WindsorREDumitruD:Anabolic Steroid Use by Athletes, Postgraduate Medicine, e(4):37–49,1988.
38.
Anonymous, The Health Letter, 33(8):1–4, 1989.
39.
HoldenSCCalvoRDSterlingJC:Anabolic Steroids in Athletics. Texas Medicine861:32–36,1990.
40.
LubellA:Does Steroid Abuse Cause—or Excuse—Violence?, The Physician and Sports-medicine, e(2):176–185,1989.
41.
21 USC Sections 351, 352, 353, 355.
42.
21 USC Sections 352, 353.
43.
21 USC Section 353(b) (1).
44.
21 USC Sections 331, 333.
45.
37 Fed Reg 16503 (15 August 1972).
46.
U.S. v. Even 453 F. Supp. 1141 (N.D. Ala. 1978).
47.
Brown v. U.S. 250 F.2d 745 (5th Cir. 1958).
48.
Doe v. U.S. 801 F.2d 1164 (Ninth Cir. 1986).
49.
21 CFR Part 1308, 1988.
50.
SomervilleJ:States Starting to Line Up Against the Illegal Distribution of Steroids. AMA News27(27 January 1989).
